Home
Charts
Search
Watchlist
Products
All IPOs
₹208 - 208
Avience Biomedicals Ltd
HealthcareIPOSME
₹208 - 208
Recognized under the Make in India Mission initiated by Prime Minister Narendra Modi, The Company commenced its journey by producing essential diagnostic kits like Viral Transport Media (VTM), Covid, HIV, HBs AG, Malaria, Dengue and others aimed at aiding medical institutions with affordable and good quality solutions. Avience Biomedicals has expanded its product range from IVD rapid test kits to include a comprehensive line of medical devices such as Serology products, Biochemistry Analyser and Biochemistry Reagents, showcasing a dedication to addressing various healthcare needs.
Lot600Min Invest₹2,49,600Face Value₹10Issue Size₹30 CrFresh Issue₹30 CrListing Price₹395CMP₹240
Timeline
18 Jun
Bidding opens
22 Jun
Bidding closes
23 Jun
Allotment
24 Jun
Refund & demat credit
25 Jun
Listing
Subscription
Subscription opens once dates are announced
Reports
Offer Details
Terms
Issue Size₹30 Cr0.15 Cr shares
Fresh Issue₹30 Cr
Face Value₹10
Lot Size600 shares
ReservationQIB 49.83% · NII 15.09% · RETAIL 35.08%
Application Sizes
Retail₹2,49,6001-1 lots
sNII₹2,49,600from 2 lots
bNII₹11,23,200from 9 lots
Managers & Registrar
Lead ManagerFintellectual Corporate Advisors Pvt Ltd
RegistrarSkyline Financial Services Pvt
Ownership & Proceeds
Shareholding
CategoryPre IPOPost IPOPromoter Group87.87%64.59%Public12.13%35.41%
Objects of the Issue
- Capital expenditure towards setting up of a new mfg unit at
- Funding the working capital requirements of the company
- General corporate purposes
Anchor Book
Bid Date17-Jun-2026Shares4,09,800Amount₹9 Cr30-day lock-in22-Jul-202690-day lock-in20-Sep-2026
Financials
Profit & Loss
| Financial Year | FY24 | FY25 | FY26 |
|---|---|---|---|
| RevenueCr | 24 | 45 | 53 |
| Operating ProfitCr | 4 | 11 | 15 |
| OPM% | 17.3 | 25.4 | 28.4 |
| PBTCr | 3 | 10 | 12 |
| PATCr | 2 | 7 | 9 |
| EPS | 7 | 19 | 22 |
Balance Sheet
| Financial Year | FY24 | FY25 | FY26 |
|---|---|---|---|
| Equity CapitalCr | 3 | 4 | 4 |
| ReservesCr | 3 | 19 | 27 |
| BorrowingsCr | 15 | 22 | 29 |
| Total AssetsCr | 35 | 56 | 75 |
Cash Flow
| Financial Year | FY24 | FY25 | FY26 |
|---|---|---|---|
| Operating Cash FlowCr | 1 | 3 | 6 |
| Investing Cash FlowCr | -4 | -10 | -13 |
| Financing Cash FlowCr | 3 | 10 | 5 |
| Net Cash FlowCr | 0 | 4 | -2 |
Strengths & Risks
Strengths · as stated in the DRHP
- Experienced Management Team and trained Employees.
- Optimal Utilization of Resources.
- Quality assurance and control.
- Cordial relationships with our clients.
Strategies · as stated in the DRHP
- Market Analysis.
- Product Portfolio Strategy.
- Research and Development.
- Operational Excellence.
- Quality Assurance and Regulatory Compliance.
- Sales and Distribution Strategy.
Risks · as stated in the DRHP
- The pharmaceutical market is subject to extensive regulation and failures to comply with the existing and future regulatory requirements in any pharmaceutical market could expose its to litigation or other liabilities, which could adversely affect the company reputation, business, financial condition and results of operations.
- The company is dependent on certain customers for a portion of its revenues. The loss of any of its major customers dues to any adverse development or significant reduction in business from its major customers may adversely affect the company business, financial condition, results of operations and future prospects.
- The company relies on suppliers for medical devices and equipment manufacturers for its trading goods, and also faces risks in sourcing raw materials and components from third parties for the manufacturing and assembly of its medical equipment. Any disruption in the supply of these goods or materials could adversely impact the company business, operations, and financial condition.
- The company Financial Statement as Restated are prepared and signed by the Peer Review Auditor who is not Statutory Auditors of its Company as required under the provisions of ICDR.
- The company business derives a significant portion of its revenue from the trading sector, and any potential instability in this area could pose a risk to the company overall performance.
- The purchase and sale of medical devices and equipment for the company trading activities is significantly dependent on related parties.